Impact of Lipoproteins on Atherobiology: Emerging Insights

Cardiol Clin. 2018 May;36(2):193-201. doi: 10.1016/j.ccl.2017.10.001.

Abstract

Apolipoprotein B-containing lipoproteins and low-density lipoprotein play a key role in atherosclerotic vascular disease. Modified forms of low-density lipoprotein drive inflammation, an integral aspect of plaque progression. High-density lipoprotein particles are equipped to protect low-density lipoprotein from enzymatic and nonenzymatic modification. Under normal conditions, high-density lipoproteins facilitate cholesterol efflux from tissues, preventing its accumulation with deleterious consequences. However, the high-density lipoprotein particles characteristic of dyslipidemic states associated with premature atherosclerosis are typically dysfunctional as a result of alteration in their metabolism and consequently their structure and composition. Such an effect indirectly enhances low-density lipoprotein atherogenicity.

Keywords: CETP; Dyslipidemia; HDL; LDL; Monocyte-derived macrophage.

Publication types

  • Review

MeSH terms

  • Atherosclerosis* / blood
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / epidemiology
  • Global Health
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Lipoproteins / blood*
  • Morbidity / trends

Substances

  • Hypolipidemic Agents
  • Lipoproteins